Condition: Resectable Pancreatic Adenocarcinoma · Sponsor: Taichung Veterans General Hospital
To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.
This description comes directly from the study's public registry record.
Yan-Shen Shan, MD, PhD · 886-6-2353535 · ysshan@mail.ncku.edu.tw
Always discuss trial participation with your own doctor first.
| Kaohsiung Chang Gung Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
| China Medical University Hospital | Taichung, Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
| National Cheng Kung University Hospital | Tainan, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06816914